BrightOwl Loader Loading

Summary

ce0702 - i am going through the rabbit hole, somewhere i just never expected to be in, where nature has no master plan, just multisets of random and simultaneous events that entangle hidden sets of association arising out of the multitude of nexus. collectively generating emerging networks of biocomplex behaviour turnouts. attractors - the attractor is a region in n-dimensional topology dictating a frequency (oscillating) between physiological rate and pathological rate. the curvatures of the n-dimensional topology of a dynamical system in the attractor satisfy distinctive constrains, physical and chemical, to linger on an attractor. there is not just one pathological or physiological outcome, there is a ratio between all pathological and physiological outcomes, this ratio is the attractor coefficient of a system. ce-sbc Analysis and interpretation on the topologies and dynamics of networks reveals systems network hidden information by looking at the disease-associated Proteins (dap) in parallel from multiple points of view.

Experiences

Current Experience

  • Managing Director


    Since February 2012
    a network approach to immune modulation - a new approach to network regulation and dynamic of disease based on peptide sequence motifs shared by the different disease-associated Proteins (dap). A network approach to immune modulation - A new approach to network regulation and dynamic of disease based on peptide sequence motifs shared by the different disease-associated proteins (DAP).

  • Senior Advisor


    Since January 2011
    science in action ltd. is a CRO company conveniently located in the weizmann science park in israel specializing in Preclinical contract Research and services. sia is renowned for accompanying Biotechnology and Drug Discovery startups from inception, proposing unconventional solutions and guiding company management through early stages of pre-Clinical work up until demonstration of proof of concept. Science in action Ltd. is a CRO company conveniently located in the Weizmann Science Park in Israel specializing in preclinical contract research and services. SIA is renowned for accompanying biotechnology and drug discovery startups from inception, proposing unconventional solutions and guiding company management through early stages of pre-clinical work up until demonstration of proof of concept.

  • CSO


    Since January 2006
    Founder of symthera, a Member of the Board of Directors, and has served as chief science officer since january 2006. chai is a graduate of ben gurion University, israel (Chemistry), montreal University, canada (Biochemistry) and the weizmann institute of science, israel (Life Sciences). chai pioneered the concept of balance in the chemokine network and developed a Biological infrastructure that has validated the concept in Animal models of disease. Founder of SymThera, a Member of the Board of Directors, and has served as Chief Science Officer since January 2006. Chai is a graduate of Ben Gurion University, Israel (Chemistry), Montreal University, Canada (Biochemistry) and The Weizmann Institute of Science, Israel (Life Sciences). Chai pioneered the concept of balance in the chemokine network and developed a biological infrastructure that has validated the concept in animal models of disease.

  • Founder


    Since May 2005
    company highlights - Drug Discovery and development for the Treatment of autoimmune diseases: multiple sclerosis, crohn's disease, arthritis, psoriasis http://www.implu.com/patent_applicant/1237390 - Biological drugs modulators of the dysfunctional immune system; high specificity, low toxicity drugs - Bioinformatics program proprietary Drug Discovery algorithm for the rational discovery and design of novel therapeutics - unique technological platform proprietary technologies for the rapid Engineering, production and screening of drug candidates - therapeutic activity drug candidates with therapeutic activity in an animal model of disease chai ezerzer: Chief Scientific Officer chai@protagonists-pal.com COMPANY HIGHLIGHTS - Drug Discovery and Development for the treatment of Autoimmune Diseases: Multiple Sclerosis, Crohn's Disease, Arthritis, Psoriasis http://www.implu.com/patent_applicant/1237390 - Biological Drugs Modulators of the dysfunctional immune system; High Specificity, Low Toxicity Drugs - Bioinformatics Program Proprietary drug discovery algorithm for the rational discovery and design of novel therapeutics - Unique Technological Platform Proprietary technologies for the rapid engineering, production and screening of drug candidates - Therapeutic Activity Drug candidates with therapeutic activity in an animal model of disease Chai Ezerzer: Chief Scientific Officer chai@protagonists-pal.com

Past Experience

  • Research Assistant / Ph.D. Student.

    January 2000 --- January 2004
    Research topic: development of cloning technology. identification and Characterization of bkt-rp3; peptide that specifically binds to the chemokines il-8 and mig, with Pharmaceutical grade affinity.

Personality

Self Assessment :
AdaptabilityAnalytical thinkingApproachabilityAttention to detail

Knowledge

LinkedIn Assessment :
Drug DiscoveryBiotechnologyBiochemistryLifesciencesLife SciencesscienceProtein chemistrymolecular biologyBioinformaticsGenomicsCell biologyClinical DevelopmentPharmaceutical IndustryDNABiomarker DiscoveryMicrobiologyAdaptive SystemsProteomicsProtein-protein InteractionsCROImmunologySystems BiologyAnimal ModelsDrug DevelopmentCell CultureTechnology transferCancerMedical DevicesAssay developmentCellCommercializationBiopharmaceuticalsGeneticsComputational BiologyELISAComplex Adaptive Systems CAS

Skills and Expertise

Self Assessment :
Biomarker Research Interpret data Molecular DiagnosticsClinical data collection

Education

  • studies toward Ph.D. in Department of Gene therapy from Hebrew University of Jerusalem in 2004
  • studies toward Ph.D. in Department of Immunology from Weizmann Institute of Science in 2000
  • M.Sc. in Department of Biological Chemistry from Weizmann Institute of Science in 1999
  • B.Sc. in Biochemistry. from Université de Montréal / University of Montreal in 1996

Languages

BrightOwl Assessment:
Self Assessment:
English
Full Proficiency
French
Full Proficiency
HEBREW
Native

Work Preferences

  • Notice Period:
    7 weeks
  • Positions I am interested in:
    Bioinformatician Molecular Biologist CSO
  • Locations I am interested in:
    Paris, France UK
  • Work From Home:
    Yes, 3 to 5 days per week
  • Work Regime:
    Permanent position :    15% FTE
    BrightOwl freelancer :    24h Hours per week :    40% Free Per Month(in coming months)
  • International:
    Yes

Area / Region

Tel Aviv, Israel

Others

Driving License
  • Yes

Similar Candidates

Other Candidates in Israel

Other Candidates in Tel Aviv-Yafo

Other Candidates

Most Recent Searches

Most Famous Searches

You might also like